Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Rhea-AI Summary

Journey Medical (Nasdaq: DERM) will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. Management will host a conference call and live audio webcast the same day at 4:30 p.m. ET to discuss results and provide a corporate update.

U.S. participants can dial 1-866-777-2509, international participants 1-412-317-5413, or register online to receive dial-in details. The webcast will be available via the Investors section of Journey Medical’s website and remain accessible for approximately 30 days after the call.

News Market Reaction – FBIO

+2.57%

10 alerts

+2.57% Session close to close

$96.91M Market Cap

0.4x Rel. Volume

In the Aug 5 session, FBIO gained 2.57%, reflecting a moderate positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The tag-specific history recorded an average move of -2.3% across two earnings-date events. This not...

Analysis

The tag-specific history recorded an average move of -2.3% across two earnings-date events. This notice supplied scheduling information rather than results, making the next release the platform checkpoint; moderate short positioning remained a sourced risk factor.

Key Figures

Results release date: August 12, 2026 Conference call time: 4:30 p.m. ET Branded FDA-approved drugs: nine drugs

3 metrics

Results release date August 12, 2026 Second quarter 2026 financial results

Conference call time 4:30 p.m. ET August 12, 2026

Branded FDA-approved drugs nine drugs Currently marketed by Journey Medical

Previous Earnings date Reports

2 past events · Latest: May 06 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Earnings date	Neutral	-5.9%	First-quarter results announcement scheduled for May 13, 2026
Mar 18	Earnings date	Neutral	+1.3%	Year-end 2025 results announcement scheduled for March 25

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date announcements produced mixed reactions, with an average move of -2.3% across two events.

Key Terms

fda

1 terms

fda regulatory

"U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, August 12, 2026 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10210876/1048acbd764. Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

FAQ

When will Journey Medical (NASDAQ: DERM) report its Q2 2026 earnings?

Journey Medical plans to report its Q2 2026 financial results on Wednesday, August 12, 2026, after U.S. markets close. According to Journey Medical, management will also host a conference call and webcast that same day at 4:30 p.m. ET.

How can investors join the Journey Medical (DERM) Q2 2026 earnings call on August 12, 2026?

Investors can join the Journey Medical Q2 2026 earnings call by dialing 1-866-777-2509 in the U.S. or 1-412-317-5413 internationally. According to Journey Medical, participants may also register online to receive dial-in details before the 4:30 p.m. ET call.

Will the Journey Medical (DERM) Q2 2026 earnings webcast be available for replay?

Yes. Journey Medical will provide a live audio webcast of the Q2 2026 call on its Investors website. According to Journey Medical, the webcast replay will remain accessible for approximately 30 days following the August 12, 2026 conference call.

Where can I access the Journey Medical (NASDAQ: DERM) Q2 2026 earnings webcast online?

The Q2 2026 earnings webcast for Journey Medical will be available on the News and Events page of the Investors section of its website. According to Journey Medical, the webcast link will stream the live call and support replay for about 30 days.

What type of company is Journey Medical (DERM) and what products does it market?

Journey Medical is a commercial-stage pharmaceutical company focused on dermatology prescription products. According to Journey Medical, it currently markets nine branded FDA-approved prescription drugs that treat common skin conditions through an efficient sales and marketing model in the United States.

What is the relationship between Journey Medical (DERM) and Fortress Biotech (FBIO)?

Journey Medical was founded by Fortress Biotech (Nasdaq: FBIO). According to Journey Medical, it operates as a commercial-stage dermatology-focused pharmaceutical company, with its common stock registered under the Exchange Act and filing periodic reports with the U.S. Securities and Exchange Commission.